EUVIMEDEUVIMED entdecken
Multizentrische StudieVergleichsstudieOpen Access · CC BY 4.0

Haploidentical hematopoietic stem cell transplantation compared to immunosuppressive therapy plus eltrombopag as first-line treatment for severe aplastic anemia patients aged 40–65: a multicenter retrospective study

Xiaohui Xiao, Guiping Chen, Cong Xu, Liangliang Wu, Xiaoyan Liu, Ming Zhou, Xiaowei Chen, Ruiqing Zhou, Wenjian Mo, Yumiao Li, Shilin Xu, Yuping Zhang und 2 weitere

Annals of Hematology · 29.09.2026 · 105 (11)

DOI: 10.1007/s00277-026-07289-2 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Annals of Hematology, online erschienen am 29.09.2026. Verfasst von Xiaohui Xiao und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The Seventh Affiliated Hospital, Sun Yat-Sen University, Shenzhen, China. Hauptthemen laut MEDLINE: Hydrazines, Benzoates, Pyrazoles, Anemia, Aplastic. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Shenzhen Science and Technology Program, Sanming Project of Medicine in Shenzhen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immunosuppressive therapy (IST) plus eltrombopag (EPAG) (IST+EPAG) is the preferred first-line treatment for severe aplastic anemia (SAA) patients over 40 years. However, direct comparison between IST+EPAG and upfront haploidentical hematopoietic stem cell transplantation (HID-HSCT) in this population remains limited. We retrospectively analyzed 123 newly diagnosed SAA patients aged 40–65 who received first-line HID-HSCT ( n = 67) or IST+EPAG ( n = 56) between 2016 and 2024. Hematological response, survival, and safety were compared. The HID-HSCT group demonstrated superior complete response (CR) rates at 3 months (17.9% vs. 5.4%), 6 months (44.8% vs. 17.9%), and 12 months (64.2% vs. 33.9%) (all P < 0.001). The 3-year overall survival (OS) was comparable between the HID-HSCT and IST+EPAG groups (78.0% vs. 80.3%, P = 0.662), and a landmark analysis conditional on survival to 6 months confirmed comparable subsequent 3-year OS (92.2% vs. 88.9%, P = 0.616). Meanwhile, the 3-year failure-free survival (FFS) was significantly higher in the HID-HSCT group among patients aged 40–49 (82.9% vs. 60.1%, P = 0.045), whereas no difference was observed in those aged 50–65 ( P = 0.984). HID-HSCT may offer more durable benefits in selected SAA patients aged 40–49, while its advantage over IST+EPAG is not evident in patients aged 50–65.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HydrazinesBenzoatesPyrazolesAnemia, AplasticHematopoietic Stem Cell TransplantationImmunosuppressive AgentsTransplantation, HaploidenticalImmunosuppression TherapyHumansRetrospective StudiesFemaleMiddle AgedAdultMaleAgedSurvival Rate

Stichwörter der Autor:innen

Haploidentical hematopoietic stem cell transplantationImmunosuppressive therapySevere aplastic anemia

Substanzen

HydrazineseltrombopagBenzoatesPyrazolesImmunosuppressive Agents

Autor:innen und Institutionen

  • Department of Hematology, The Seventh Affiliated Hospital, Sun Yat-Sen University, Shenzhen, China.
  • Department of Hematology, Guangzhou First People's Hospital, Institute of Blood Transfusion and Hematology, Guangzhou Medical University, Guangzhou, China.
  • Department of Hematology, Guangzhou First People's Hospital, South China University of Technology, Guangzhou, China.
  • Department of Hematology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
  • Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.
  • Department of Hematology, Guangzhou First People's Hospital, Institute of Blood Transfusion and Hematology, Guangzhou Medical University, Guangzhou, China. jnzhangyuping@163.com.

Förderung

  • National Natural Science Foundation of China
  • Shenzhen Science and Technology Program
  • Sanming Project of Medicine in Shenzhen
  • National Key R&D program of China
  • Innovative Clinical Technique of Guangzhou
  • 2019 Annual Research Project of the China Marrow Donor Program

Zitieren

APA

Xiao, X., Chen, G., Xu, C., Wu, L., Liu, X., Zhou, M., Chen, X., Zhou, R., Mo, W., Li, Y., Xu, S., Zhang, Y., Lin, D., & Wang, S. (2026). Haploidentical hematopoietic stem cell transplantation compared to immunosuppressive therapy plus eltrombopag as first-line treatment for severe aplastic anemia patients aged 40–65: a multicenter retrospective study. Annals of Hematology, 105(11). https://doi.org/10.1007/s00277-026-07289-2

Vancouver

Xiao X, Chen G, Xu C, Wu L, Liu X, Zhou M, et al. Haploidentical hematopoietic stem cell transplantation compared to immunosuppressive therapy plus eltrombopag as first-line treatment for severe aplastic anemia patients aged 40–65: a multicenter retrospective study. Annals of Hematology. 2026;105(11). doi:10.1007/s00277-026-07289-2

BibTeX
@article{Xiao2026,
  author = {Xiao, Xiaohui and Chen, Guiping and Xu, Cong and Wu, Liangliang and Liu, Xiaoyan and Zhou, Ming and Chen, Xiaowei and Zhou, Ruiqing and Mo, Wenjian and Li, Yumiao and Xu, Shilin and Zhang, Yuping and Lin, Dongjun and Wang, Shunqing},
  title = {Haploidentical hematopoietic stem cell transplantation compared to immunosuppressive therapy plus eltrombopag as first-line treatment for severe aplastic anemia patients aged 40–65: a multicenter retrospective study},
  journal = {Annals of Hematology},
  year = {2026},
  volume = {105},
  number = {11},
  doi = {10.1007/s00277-026-07289-2}
}
Kostenlos starten →